Cabozantinib combined with osimertinib has also shown potential in overcoming AXL-mediated resistance in EGFR-mutated NSCLC.168 Multiple trials (NCT00596648, NCT01866410, and NCT01708954) are exploring the combination of cabozantinib with erlotinib to address EGFR-TKI resistance in NSCLC, while cabozantinib combined with panitumumab has demonstrated a favorable safety profile and encouraging activity in RAS wild-type colorectal cancer (NCT02008383).258. This evidence concerns the gene AXL and colorectal cancer.